We have observed and seen that trends are changing quickly amongst the people. But interestingly, trends and preferences are changing in industries too. IT or related companies are slowly entering in to biopharmaceuticals and diagnostics business. There are few leaner linking between pharma and IT companies. For example, if we want to develop any sophisticated medical device, it is required to develop some software or codings to make that device workable. I mean to write that they are very new in medical devices portfolio. Diversifying full portfolio is never easier but if you are starting today, one day you will surely reach your goal and it will provide more competition to already established companies. The editorial of this issue highlighting this scenario and provides complete idea on new trends.
Current issue contain overview on potent target for cancer treatment through tumor hypoxia necrosis; It also have reviews on cerebral aging and neurological disorders, cyclodextrins and their pharmaceutical applications, huntington’s disease, prolotherapy for arthritis, drug delivery approaches to improve bioavailability in brain, rudraksha and amphiphilic janus like particles for biomedical application.
This issue has researches like antimicrobial activity of padigalinga chenduram against enteric pathogens, degradation study of ciprofloxacin hydrochloride, bromhexine hydrochloride and their combined pharmaceutical dosage form, formulation and evaluation of sustain release tablets of ramipril, investigation of hydrogel thickened microemulsion of meloxicam, estimation of amiloride and torsemide in their combined pharmaceutical dosage form by rp-hplc method, estimation of olmesartan medoxomil and cilnidipine, development and validation of rp-hplc method for simultaneous estimation of ilaprazole and domperidone, analytical method development and validation for simultaneous estimation of paracetamol and propyphenazone, pharmacognostic evaluation on fruits of gmelina arborea.